How does this study impact clinical practice?
AHCL therapy achieved high %TIR with low %TBR (time below range) in this study in patients with T1D.
With a set point of 100 mg/dL and an AIT (active insulin time) setting of 2-3 hours, nearly 80% of participants achieved a TIR
>70% without an increase in hypoglycemia.
AHCL therapy further improved glycemia control.